Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

FDA completes its review of Lannett’s IND for biosimilar insulin glargine

by | Jan 21, 2022

Lannett announced that the FDA has completed its review of the Investigational New Drug Application for biosimilar insulin glargine.  Lannett plans to complete the clinical trials by early 2023, with a potential launch in early 2024.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News